Skip to main content
Join

Diagnostics

"Inspirational quote will be inserted here"
- The author of the quote

This category is dedicated to the field of diagnostics, which focuses on the rapid and accurate identification of pathogens and their resistance profiles. Effective diagnostics are a cornerstone of antimicrobial stewardship, as they provide the crucial information needed to move away from broad-spectrum antibiotic use towards targeted, effective treatment.

Content covers the development and application of `Rapid Diagnostic Tests (RDTs)`, `Point-of-Care (POC)` devices, advanced `Antimicrobial Susceptibility Testing (AST)` methods, and `molecular diagnostics`. The category also includes the search for biomarkers that can differentiate between bacterial and viral infections, a key strategy to reduce unnecessary antibiotic prescribing. Ultimately, the goal is to ensure the right drug is used for the right bug at the right time
Diagnostic tools and technologies play a crucial role in the effective management of bacterial infections. Accurate and timely diagnostic tools help clinicians identify the specific pathogen responsible for an infection, which enables targeted treatment with the right antibiotic, at the correct dose, and for the appropriate duration. This precision avoids both undertreatment and unnecessary use of antibiotics, which are key drivers of antimicrobial resistance (AMR), i.e. rational pharmacotherapy. Improved diagnostic modalities also allow for monitoring resistance patterns within hospitals and health systems, helping to track which bacteria are becoming harder to treat. Faster and more accurate tests empower clinicians to choose targeted therapies instead of broad-spectrum antibiotics, further reducing the risk of resistance and improving patient outcomes.

In summary, antimicrobial diagnostics are essential for:

  • Ensuring effective and responsible antibiotic use
  • Preventing unnecessary prescriptions
  • Monitoring resistance trends
  • Supporting antimicrobial stewardship programs

These functions and novel solutions in the field collectively help slow the spread of AMR and preserve the effectiveness of existing antibiotics which is the very focus and purpose of this category

News

20 February 2026
Author: Chris Dall
Source: umn.edu
DEBUG: Construction & facilities
Trump administration seeks to build alternative to WHO surveillance
According to reporting by the Washington Post, the Department of Health and Human Services (HHS) is seeking up to $2 billion a year to build a worldwide disease-monitoring system that would recreate systems such as laboratories, data-sharing networks, and rapid-response systems" that the United States once helped build for the WHO. The Post notes that the price tag is roughly three times the $680 million the US government contributed annually to the WHO before it left the organization. The Trump administration formally withdrew from the WHO on January 22, saying that the agency had "abandoned its core mission and acted repeatedly against the interests of the United States." "Although the United States was a founding member and the WHO's largest financial contributor, the organization pursued a politicized, bureaucratic agenda driven by nations hostile to American interests," HHS Secretary Robert F. Kennedy Jr. and Secretary of State Marco Rubio said in a joint statement. In response to a request from CIDRAP News for confirmation and further clarification of the Post's reporting, HHS spokesman Andrew Nixon said, "HHS is working with the White House in a deliberative, interagency process on the path forward for global health and foreign assistance that first and foremost protects Americans." The decision to leave the WHO has been widely condemned by global health and infectious disease experts, who've warned that it will jeopardize disease surveillance and the ability to keep the country safe from outbreaks."
Read
16 February 2026
Author: Roche Diagnostics
Source: Bionity.com
DEBUG: Diagnostics
Roche opens new high-tech innovation center for 300 million euros in Bavaria
In future, a good 1,000 of the site's approximately 7,700 employees will find a new home for the diagnostics research and development of the future on an area the size of three soccer pitches. The Innovation Center was officially inaugurated on 12 February 2026 in the presence of Minister President Markus Söder, Federal Minister of the Interior Alexander Dobrindt, Federal Minister of Research, Technology and Space Dorothee Bär, Thomas Schinecker, CEO of the Roche Group and the management of Roche's German sites. The high level of automation and digital networking in the new building is continued in the spatial design: instead of traditional departmental structures, Roche relies on process-based laboratory environments in which teams work more closely together across departmental boundaries and share equipment. Intelligent energy management and the use of existing energy and supply systems at the site - such as the use of a low-temperature network from waste heat or a photovoltaic system with a total electrical output of 130 kilowatts on the roof of the building - enable CO₂-free operation.
Read
13 February 2026
Author: Delthia Ricks
Source: Medical Xpress
DEBUG: Antimicrobial insights
Can tuberculosis treatment be safely shortened? New studies look inside the lungs for answers
Across the spectrum of human afflictions - from cancer to heart disease to rare genetic conditions - medical investigators are continually attempting to break new ground by developing better methods of treating patients. It is a global scientific enterprise in which experimental medications are subjected to rigorous testing, forgotten drugs are analyzed for new applications, and existing treatments are reevaluated. Dozens upon dozens of studies like these are charting a path forward.
Read

Events

View all

Jobs

View all